Department of Otorhinolaryngology, Head and Neck Surgery, Zurich University Hospital and University of Zurich, Frauenklinikstrasse 24, CH-8091, Zurich, Switzerland.
Department of Pathology and Molecular Pathology, Zurich University Hospital and University of Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland.
Sci Rep. 2019 Sep 4;9(1):12724. doi: 10.1038/s41598-019-49215-9.
Objective was to analyze the role of PD-L1 and its relation to demographic, patho-clinical and outcome parameters in salivary gland carcinoma (SGC) patients. Patients treated for salivary gland carcinomas between 1994 and 2010 were included. A retrospective chart review for baseline characteristics, pathohistological, clinical and outcome data was performed. Immunohistochemistry for PD-L1 was performed using tissue microarrays. PD-L1 expression was assessed in tumor cells and tumor-infiltrating immune cells (TIIC) and statistical analysis with regard to baseline and outcome data was performed. Expression of PD-L1 (by means ≥1% of the cells with PD-L1 positivity) was present in the salivary gland carcinoma cells of 17%, in the TIIC of 20% and in both tumor cells and TIIC of 10% the patients. PD-L1 expression in tumor cells and both tumor cells and TIIC was related to tumor grading (p = 0.035 and p = 0.031, respectively). A trend towards higher grading was also seen for PD-L1 expression in TIICs (p = 0.058). Patients with salivary duct carcinomas and PD-L1 expressing TIICs showed a significantly worse DFS and OS (p = 0.022 and p = 0.003, respectively), those with both tumor cells and TIIC expressing PD-L1 a significantly worse DFS (p = 0.030). PD-L1 expression is present in 17% and 20% of salivary gland carcinoma cells and TIIC. Ten percent of the patient showed a PD-L1 positivity in both tumor cells and TIIC. This is related to high tumor grading and therefore might be a negative prognostic factor.
目的在于分析 PD-L1 的作用及其与唾液腺癌（SGC）患者的人口统计学、病理临床和结局参数的关系。纳入了 1994 年至 2010 年间接受唾液腺癌治疗的患者。对基线特征、病理组织学、临床和结局数据进行了回顾性图表审查。使用组织微阵列进行了 PD-L1 的免疫组织化学检测。评估了 PD-L1 在肿瘤细胞和肿瘤浸润免疫细胞（TIIC）中的表达，并对基线和结局数据进行了统计分析。在 17%的唾液腺癌患者中，在肿瘤细胞中存在 PD-L1 表达，在 20%的 TIIC 中存在 PD-L1 表达，在 10%的患者的肿瘤细胞和 TIIC 中均存在 PD-L1 表达。肿瘤细胞和肿瘤细胞及 TIIC 中的 PD-L1 表达与肿瘤分级相关（p=0.035 和 p=0.031）。TIIC 中 PD-L1 表达的分级也呈升高趋势（p=0.058）。具有 PD-L1 表达的 TIIC 的涎导管癌患者的 DFS 和 OS 显著更差（p=0.022 和 p=0.003），具有肿瘤细胞和 TIIC 均表达 PD-L1 的患者的 DFS 显著更差（p=0.030）。PD-L1 在 17%和 20%的唾液腺癌细胞和 TIIC 中表达。10%的患者在肿瘤细胞和 TIIC 中均表现出 PD-L1 阳性。这与高肿瘤分级有关，因此可能是一个负预后因素。
